← All trials
NCT05050084
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2021
- Primary completion
- Apr 30, 2032
- Completion date
- Apr 30, 2037
- First posted
- Sep 20, 2021
- Last posted
- Sep 23, 2021
- Enrollment
- 2050
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NRG OncologyLead sponsor
- National Cancer Institute (NCI)Collaborator
- NRG OncologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.